Remove Blog Remove FDA Remove Regulatory Compliance Remove US Department of Health and Human Services
article thumbnail

December 2023 Regulatory Compliance Updates

Verisys

– The best resource for monthly healthcare regulatory compliance updates. US S3193 DEA: The DEA and Department of Health and Human Services (HHS) has announced the extension of current telemedicine flexibilities through December 31, 2024. This bill is currently in committee.

article thumbnail

5 Key Facts to Know About FDA’s Emergency Use Authorization Process

Exeed Regulatory Compliance

How Emergency Use Authorization of Medical Products Helps Provide Relief During a COVID-19 Major Crisis. As we write this blog, over 60,000 new infections are being reported on a daily basis in the United States, with a cumulative total of over 4 million cases and over 150,000 deaths reported since the pandemic first began here.

FDA 52
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How the Medical Industry Can Help Combat the Current Coronavirus Crisis

Exeed Regulatory Compliance

It rapidly caused a widespread epidemic in China and has spread to over 50 countries outside of China with more than 90,000 confirmed cases and 3000 deaths at the time of this blog article. Secretary of the Department of Health and Human Services (HHS) has declared a public health emergency.

article thumbnail

SQA Regulatory Surveillance Summary | Monthly Update 2022 – July/August

SQA

SQA Regulatory Surveillance Summary for July and August 2022. Health Canada. Health Canada is warning consumers about counterfeit BTNX Rapid Response COVID-19 antigen rapid test kits (25-pack boxes) found in Ontario. products in color and typeface and uses the BTNX Inc. and one distributor, Healthful Plus.

article thumbnail

The BFDs – The Ten Best Prescription Drug/Medical Device Decisions of 2023

Drug & Device Law

Executive Health Resources, Inc. , Executive Health Resources, Inc. , United States Department of Health and Human Services , 58 F.4th This year’s Drug & Device Law Blog top ten decisions of the year reinforced preemption – the most powerful defense we can assert. Polansky v. 3d 239 (Cal.

FDA 105